Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report ; volume:16 ; number:1 ; day:7 ; month:7 ; year:2016 ; pages:1-5 ; date:12.2016
BMC cancer ; 16, Heft 1 (7.7.2016), 1-5, 12.2016
- Urheber
-
Casadei Gardini, Andrea
- Beteiligte Personen und Organisationen
-
Chiadini, Elisa
Faloppi, Luca
Marisi, Giorgia
Delmonte, Angelo
Scartozzi, Mario
Loretelli, Cristian
Lucchesi, Alessandro
Oboldi, Devil
Dubini, Alessandra
Frassineti, Giovanni Luca
Ulivi, Paola
SpringerLink (Online service)
- DOI
-
10.1186/s12885-016-2463-2
- URN
-
urn:nbn:de:1111-2016071111231
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 14.08.2025, 10:53 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Casadei Gardini, Andrea
- Chiadini, Elisa
- Faloppi, Luca
- Marisi, Giorgia
- Delmonte, Angelo
- Scartozzi, Mario
- Loretelli, Cristian
- Lucchesi, Alessandro
- Oboldi, Devil
- Dubini, Alessandra
- Frassineti, Giovanni Luca
- Ulivi, Paola
- SpringerLink (Online service)
Ähnliche Objekte (12)
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma
BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature
Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells
Disruption of mutated BRAF signaling modulates thyroid cancer phenotype
Brautpaar Braf
Braf, Albin
TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF V600E /TERT promoter double-mutated glioma
Combination treatment effects of BRAF (B-RAF proto-oncogene, serine/threonine kinase) inhibitors and HSP90 (heat shock protein 90) inhibitors in BRAF-mutated colorectal cancer cell lines
Resistance to BRAF inhibition explored through single circulating tumour cell molecular profiling in BRAF-mutant non-small-cell lung cancer
Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
Drug-induced colitis on BRAF and MEK inhibitors for BRAF V600E-mutated non-small cell lung cancer: a case report
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma
BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature
Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells
Disruption of mutated BRAF signaling modulates thyroid cancer phenotype
Brautpaar Braf
Braf, Albin
TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF V600E /TERT promoter double-mutated glioma
Combination treatment effects of BRAF (B-RAF proto-oncogene, serine/threonine kinase) inhibitors and HSP90 (heat shock protein 90) inhibitors in BRAF-mutated colorectal cancer cell lines
Resistance to BRAF inhibition explored through single circulating tumour cell molecular profiling in BRAF-mutant non-small-cell lung cancer
Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
Drug-induced colitis on BRAF and MEK inhibitors for BRAF V600E-mutated non-small cell lung cancer: a case report
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma
BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature
Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells
Disruption of mutated BRAF signaling modulates thyroid cancer phenotype
Brautpaar Braf
Braf, Albin
TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF V600E /TERT promoter double-mutated glioma
Combination treatment effects of BRAF (B-RAF proto-oncogene, serine/threonine kinase) inhibitors and HSP90 (heat shock protein 90) inhibitors in BRAF-mutated colorectal cancer cell lines
Resistance to BRAF inhibition explored through single circulating tumour cell molecular profiling in BRAF-mutant non-small-cell lung cancer
Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer